Literature DB >> 33299127

ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways.

Tingjian Zu1,2,3, Diana Wang3,4, Shuyun Xu3, Catherine A A Lee5, Ellen Zhen3, Charles H Yoon6, Phammela Abarzua3, Shuangshuang Wang1, Natasha Y Frank5,7,8, Xunwei Wu9,10, Christine G Lian11, George F Murphy12,13.   

Abstract

Activating transcription factor 3 (ATF-3), a cyclic AMP-dependent transcription factor, has been shown to play a regulatory role in melanoma, although its function during tumor progression remains unclear. Here, we demonstrate that ATF-3 exhibits tumor suppressive function in melanoma. Specifically, ATF-3 nuclear expression was significantly diminished with melanoma progression from nevi to primary to metastatic patient melanomas, correlating low expression with poor prognosis. Significantly low expression of ATF-3 was also found in cultured human metastatic melanoma cell lines. Importantly, overexpression of ATF-3 in metastatic melanoma cell lines significantly inhibited cell growth, migration, and invasion in vitro; as well as abrogated tumor growth in a human melanoma xenograft mouse model in vivo. RNA sequencing analysis revealed downregulation of ERK and AKT pathways and upregulation in apoptotic-related genes in ATF-3 overexpressed melanoma cell lines, which was further validated by Western-blot analysis. In summary, this study demonstrated that diminished ATF-3 expression is associated with melanoma virulence and thus provides a potential target for novel therapies and prognostic biomarker applications.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33299127      PMCID: PMC8091967          DOI: 10.1038/s41374-020-00516-y

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  45 in total

1.  ATF3 regulates the stability of p53: a link to cancer.

Authors:  Chunhong Yan; Douglas D Boyd
Journal:  Cell Cycle       Date:  2006-05-01       Impact factor: 4.534

Review 2.  Prevention and early detection strategies for melanoma and skin cancer. Current status.

Authors:  H K Koh; A C Geller; D R Miller; T A Grossbart; R A Lew
Journal:  Arch Dermatol       Date:  1996-04

Review 3.  ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component?

Authors:  Tsonwin Hai; Christopher C Wolford; Yi-Seok Chang
Journal:  Gene Expr       Date:  2010

Review 4.  A systematic review of worldwide incidence of nonmelanoma skin cancer.

Authors:  A Lomas; J Leonardi-Bee; F Bath-Hextall
Journal:  Br J Dermatol       Date:  2012-05       Impact factor: 9.302

Review 5.  Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.

Authors:  Antoine Millet; Anthony R Martin; Cyril Ronco; Stéphane Rocchi; Rachid Benhida
Journal:  Med Res Rev       Date:  2016-08-29       Impact factor: 12.944

Review 6.  Molecular biology of normal melanocytes and melanoma cells.

Authors:  Bizhan Bandarchi; Cyrus Aleksandre Jabbari; Ali Vedadi; Roya Navab
Journal:  J Clin Pathol       Date:  2013-03-23       Impact factor: 3.411

Review 7.  ATF3 transcription factor and its emerging roles in immunity and cancer.

Authors:  Matthew R Thompson; Dakang Xu; Bryan R G Williams
Journal:  J Mol Med (Berl)       Date:  2009-08-25       Impact factor: 4.599

8.  Downregulated TRPV1 Expression Contributes to Melanoma Growth via the Calcineurin-ATF3-p53 Pathway.

Authors:  Yuqi Yang; Weinan Guo; Jingjing Ma; Peng Xu; Weigang Zhang; Sen Guo; Lin Liu; Jinyuan Ma; Qiong Shi; Zhe Jian; Ling Liu; Gang Wang; Tianwen Gao; Zheyi Han; Chunying Li
Journal:  J Invest Dermatol       Date:  2018-03-23       Impact factor: 8.551

9.  Opposing roles for calcineurin and ATF3 in squamous skin cancer.

Authors:  Xunwei Wu; Bach-Cuc Nguyen; Piotr Dziunycz; Sungeun Chang; Yang Brooks; Karine Lefort; Günther F L Hofbauer; G Paolo Dotto
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

10.  Activating transcription factor 3 promotes malignance of lung cancer cells in vitro.

Authors:  Xuebing Li; Xuexia Zhou; Yongwen Li; Lingling Zu; Hongli Pan; Boning Liu; Wang Shen; Yaguang Fan; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2017-02-27       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.